Reverse Phase Protein Array
In this section
- Antibody specificity and characterisation
- Biomarker discovery and quantification
- Drug target discovery
- Glycan arrays and glycomics
- Human Proteome Array
- Label-free (SPRi)
- Reverse Phase Protein Array
- Small molecule microarrays
- Spatial transcriptomics
Reverse Phase Protein Array (RPPA)
A reverse phase protein array (RPPA) experiment begins with printing cell lysates or liquid biopsies as individual spots onto membrane-coated slides. The samples are permanently immobilised in a grid layout or array, and once blocked (as per a Western blot) the samples can be interrogated with antibodies to detect and quantify biomarkers of interest.
The RPPA technique enables researchers to compare and contrast the molecular profiles of thousands of patients in a single experiment. Using Arrayjet technology, up to 70,000 samples can be printed on a single slide.
Researchers at the University of Kentucky use a Marathon Argus non-contact microarray printer for their RPPA experiments.
Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification
Jan C Brase, Heiko Mannsperger, Holger Fröhlich, Stephan Gade, Christian Schmidt, Stefan Wiemann, Tim Beissbarth, Thorsten Schlomm, Holger Sültmann and Ulrike Korf
High-density serum/plasma reverse phase protein arrays
Cecilia Hellström, Tea Dodig-Crnković, Mun-Gwan Hong, Jochen M Schwenk, Peter Nilsson and Ronald Sjöberg
"Arrayjet’s Marathon Argus was selected to support and integrate with our Zeptosens RPPA microarray platform and this has helped produce faster results for both in vivo and in vitro studies. We can increase the printing of high throughput of biomarkers whilst significantly optimising quality. We’re delighted with this ability to scale up our microarray printing.”
Dr Ashraf Elamin, Manager Proteomics, Phillip Morris International